Advanced Micro Devices vs Summit Therapeutics Inc — how do they compare? Advanced Micro Devices trades at $480.2 (market cap $774.32B), while Summit Therapeutics Inc trades at $15.34 (market cap $12.06B). The key difference: Advanced Micro Devices is far larger — about 64.2× Summit Therapeutics Inc's market cap, and Advanced Micro Devices is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| AMD | SMMT | |
|---|---|---|
Market Cap | $774.32B | $12.06B |
Sector | Technology | Health |
52-Week High | $580.91 | $26.98 |
52-Week Low | $151.14 | $12.55 |
Enterprise Value | $765.48B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
AMD trades at $474.32, down 1.87% on the day, with a bearish technical signal but strong fundamental momentum. The stock shows elevated valuation metrics (P/E 119.79, P/S 18.75) despite impressive revenue growth to $34.64B in 2025 and consistent earnings beats. Analyst consensus remains strongly bullish with a $615.11 price target, while recent news highlights AMD's positioning in the competitive AI semiconductor market.
AMD presents a growth story driven by AI and data center demand, with projected revenue reaching $41.3B in 2026. However, high valuations and intense competition from NVIDIA represent significant risks. The stock offers substantial upside to analyst targets but requires careful monitoring of execution and market share dynamics.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →